+

WO2003086389A1 - Utilisation d'un compose photosensible pour la preparation d'une composition pharmaceutique destinee a traiter les brulures, et methode de traitement de brulures - Google Patents

Utilisation d'un compose photosensible pour la preparation d'une composition pharmaceutique destinee a traiter les brulures, et methode de traitement de brulures Download PDF

Info

Publication number
WO2003086389A1
WO2003086389A1 PCT/NL2003/000270 NL0300270W WO03086389A1 WO 2003086389 A1 WO2003086389 A1 WO 2003086389A1 NL 0300270 W NL0300270 W NL 0300270W WO 03086389 A1 WO03086389 A1 WO 03086389A1
Authority
WO
WIPO (PCT)
Prior art keywords
burn
substituted
photosensitiser
bromine
iodine
Prior art date
Application number
PCT/NL2003/000270
Other languages
English (en)
Inventor
Johannes Wilhelminus Maria Lagerberg
Johannes Joseph Schuitmaker
Thomas Marinus Albert Remko Dubbelman
Saskia Anna Geertruida Lambrechts
Adriana Hendrika Langeveld-Klerks
Original Assignee
Photobiochem Leiden Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photobiochem Leiden Nv filed Critical Photobiochem Leiden Nv
Priority to AU2003235434A priority Critical patent/AU2003235434A1/en
Publication of WO2003086389A1 publication Critical patent/WO2003086389A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to the use of a compound for the treatment of burns.
  • the invention therefore relates specifically to the application of a photosensitiser for the preparation of a pharmaceutical preparation for the treatment of burns.
  • a pharmaceutical preparation can be applied to the burn, subsequent to which the burn is exposed to light.
  • the light is preferably directed onto the burn.
  • a photosensitiser is understood to be a compound, which in the presence of oxygen due to absorption of light generates reactive oxygen species, which include singlet oxygen and oxygen radicals.
  • reactive oxygen species include singlet oxygen and oxygen radicals.
  • the effect of reactive oxygen species is that microorganisms are inactivated or even killed while causing relatively little stress on the cells of the body, whereas when using antibiotics, there is much more stress.
  • An important advantage of the invention is that even antibiotic-resistant microorganisms can be effectively combatted.
  • the pharmaceutical preparation may contain an antibiotic, by which it may be possible to procure an additional effect.
  • microorganism comprises Gram-positive and Gram-negative bacteria.
  • the treatment of a burn also in- eludes the treatment of a burn that has received a skin graft.
  • the photosensitiser has the formula (I)
  • halogen atom selected from fluorine, chlorine, bromine and iodine; - linear or branched (C1-C20) alkyl, (C1-C20) alkoxy, (Ci-
  • halogen atom selected from fluorine, chlorine, bromine and iodine
  • This compound - wherein the pharmaceutically accept- able counterion is, for example, chloride - is according to experimental research the most effective of a representative series of studied compounds with the formula (I) .
  • the pharmaceutical preparation has the form of a preparation to be applied topically and more particularly, the pharmaceutical preparation is a gel, lotion, ointment, cream and preferably a spray or aerosol.
  • the pharmaceutical preparation may be applied in doses.
  • a spray or an aerosol is used, since with a spray or aerosol the lowest possible dose of photosensitiser provides the highest concentration of photosensitiser on the surface of the wound to be treated in order to effectively damage, inhibit the growth of, or even kill microorganisms present on the burn.
  • the photosensitiser may also be incorporated in a wound dressing for covering the burn for a short or longer time.
  • the dressing must be light- and oxygen-permeable.
  • the photosensitiser may be bound covalently to the dressing. In that case there is a full guarantee that the body will not be challenged with such a substance.
  • the invention also relates to a method of treating a burn, which is characterised in that a photosensitiser is topically applied to a burn of a mammal, and the burn is irradiated with light of a wavelength that is absorbed by the photosensitiser.
  • the photosensitiser is preferably a compound with the formula (I) as described above, and in particular the salt of monophenyl-tri (N-methyl-4-pyridyl) -porphyrin and a pharmaceutically acceptable counterion.
  • the reactive oxygen species are formed through the presence of oxygen in the air.
  • the burn is contacted with a gas having an oxygen concentration of more than 30%, and preferably more than 50%, subsequent to which the burn is irradiated in the presence of the gas.
  • Fig. 1 represents a graph of the inactivation of Staphylococcus aureus
  • Fig. 2 represents a graph of the inactivation of
  • Human blood plasm was obtained from the buffy coat (Bloedbank Leiden-Haagouchen, Leiden, the Netherlands) by centrifugation at 2000 rpm for 10 min.
  • Human serumalbumin (HSA) CealbT was obtained from CLB, Am- sterdam, the Netherlands.
  • Staphylococcus aureus and Pseudomonas aeruginosa isolated from burns were cultured aerobically in liquid brain heart infusion medium
  • Fig. 1 shows that the Gram-positive bacterium Staphylococcus aureus can be inactivated very effectively even at relatively low concentrations of TriP(4).
  • Light dose 30 mW/cm 2 as determined with an IL 1400A photometer equipped with a SEL033 detector (International Light, Newburyport, MA, USA). Key to symbols: 0 3:1 ⁇ M, r 6:25 ⁇ M en ⁇ 12:,-5 ⁇ M TriP(4) .
  • the Gram-negative bacterium Pseudomonas aeruginosa can also be effectively inactivated.
  • the radiation intensity was again 30 mW/cm 2 .
  • Each curve is the mean of three measurements (three different batches of isolated material) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'application d'un photosensibilisant pour la préparation d'une composition pharmaceutique destinée au traitement des brûlures. L'invention se rapporte en outre à une méthode de traitement d'une brûlure. A cette fin, selon l'invention, le photosensibilisant est appliqué topiquement sur une brûlure d'un mammifère, la brûlure étant alors exposée à une lumière d'une longueur d'onde donnée absorbée par le photosensibilisant.
PCT/NL2003/000270 2002-04-09 2003-04-09 Utilisation d'un compose photosensible pour la preparation d'une composition pharmaceutique destinee a traiter les brulures, et methode de traitement de brulures WO2003086389A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003235434A AU2003235434A1 (en) 2002-04-09 2003-04-09 Use of a photosensitising compound for the preparation of a pharmaceutical composition for treating of burns, and a method of treating burns

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1020336A NL1020336C2 (nl) 2002-04-09 2002-04-09 Toepassing van een verbinding voor de bereiding van een farmaceutisch preparaat voor het behandelen van brandwonden, en een werkwijze voor het behandelen van brandwonden.
NL1020336 2002-04-09

Publications (1)

Publication Number Publication Date
WO2003086389A1 true WO2003086389A1 (fr) 2003-10-23

Family

ID=29244970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000270 WO2003086389A1 (fr) 2002-04-09 2003-04-09 Utilisation d'un compose photosensible pour la preparation d'une composition pharmaceutique destinee a traiter les brulures, et methode de traitement de brulures

Country Status (3)

Country Link
AU (1) AU2003235434A1 (fr)
NL (1) NL1020336C2 (fr)
WO (1) WO2003086389A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069273A1 (fr) * 2003-02-05 2004-08-19 Photobiochem N.V. Utilisation d'un compose de porphyrine pour traiter des champignons cutanes
GB2415372A (en) * 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
US7244841B2 (en) 2002-12-23 2007-07-17 Destiny Pharma Limited Porphyrin derivatives and their use in photodynamic therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033463A2 (fr) * 1994-06-02 1995-12-14 Bar-Ilan University Compositions antibiotiques synergique contenant une porphyrine et un antibiotique
WO1996005862A1 (fr) * 1994-08-19 1996-02-29 L'oreal Utilisation de sels de derives cationiques de porphine comme agents photosensibilisants de bacteries de type gram-negatif
WO1998034644A1 (fr) * 1997-02-11 1998-08-13 Qlt Phototherapeutics, Inc. Compositions et articles pour attenuer les consequences de l'inflammation
WO1998039011A1 (fr) * 1997-03-06 1998-09-11 The General Hospital Corporation Conjugues de photosensibilisant destines au ciblage de pathogenes
WO2002004073A2 (fr) * 2000-07-07 2002-01-17 Optomed Optomedical Systems Gmbh Dispositif de rayonnement therapeutique
WO2003011265A2 (fr) * 2001-07-26 2003-02-13 Photocure Asa Methode

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033463A2 (fr) * 1994-06-02 1995-12-14 Bar-Ilan University Compositions antibiotiques synergique contenant une porphyrine et un antibiotique
WO1996005862A1 (fr) * 1994-08-19 1996-02-29 L'oreal Utilisation de sels de derives cationiques de porphine comme agents photosensibilisants de bacteries de type gram-negatif
WO1998034644A1 (fr) * 1997-02-11 1998-08-13 Qlt Phototherapeutics, Inc. Compositions et articles pour attenuer les consequences de l'inflammation
WO1998039011A1 (fr) * 1997-03-06 1998-09-11 The General Hospital Corporation Conjugues de photosensibilisant destines au ciblage de pathogenes
WO2002004073A2 (fr) * 2000-07-07 2002-01-17 Optomed Optomedical Systems Gmbh Dispositif de rayonnement therapeutique
WO2003011265A2 (fr) * 2001-07-26 2003-02-13 Photocure Asa Methode

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MERCHAT M ET AL: "Studies on the mechanism of bacteria photosensitization by meso-substituted cationic porphyrins.", JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B BIOLOGY, vol. 35, no. 3, 1996, pages 149 - 157, XP002246775, ISSN: 1011-1344 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244841B2 (en) 2002-12-23 2007-07-17 Destiny Pharma Limited Porphyrin derivatives and their use in photodynamic therapy
WO2004069273A1 (fr) * 2003-02-05 2004-08-19 Photobiochem N.V. Utilisation d'un compose de porphyrine pour traiter des champignons cutanes
GB2415372A (en) * 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent

Also Published As

Publication number Publication date
NL1020336C2 (nl) 2003-10-13
AU2003235434A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
EP1392666B1 (fr) Derives de bleu de methylene actifs sur le plan biologique
Jori Photodynamic therapy of microbial infections: state of the art and perspectives
Hakimiha et al. The susceptibility of Streptococcus mutans to antibacterial photodynamic therapy: a comparison of two different photosensitizers and light sources
Bonnett et al. Water disinfection using photosensitizers immobilized on chitosan
JP6263465B2 (ja) 皮膚および創傷における使用のための組成物
Nitzan et al. The mechanism of photodynamic inactivation of Staphylococcus aureus by deuteroporphyrin
US20120277660A1 (en) Composition and method for treatment of mrsa
Kashef et al. Phototoxic effect of hypericin alone and in combination with acetylcysteine on Staphylococcus aureus biofilms
Mamone et al. Photodynamic inactivation of Gram-positive bacteria employing natural resources
Braz et al. Photodynamic inactivation of methicillin-resistant Staphylococcus aureus on skin using a porphyrinic formulation
Karrer et al. Photodynamic inactivation of staphylococci with 5-aminolaevulinic acid or photofrin
Yang et al. Effects of ultraviolet irradiation on the antibacterial activity of TiO2 nanotubes
Kreitner et al. Haematoporphyrin-and sodium chlorophyllin-induced phototoxicity towards bacteria and yeasts–a new approach for safe foods
WO2003086389A1 (fr) Utilisation d'un compose photosensible pour la preparation d'une composition pharmaceutique destinee a traiter les brulures, et methode de traitement de brulures
Wang et al. An effective zinc phthalocyanine derivative against multidrug-resistant bacterial infection
WO2003035553A9 (fr) Procede de decontamination microbiologique d'eau au moyen d'agents photosensibles
Popova Antibacterial activity of the original dietary supplement oxidal® in vitro
Bordin et al. Photobiological properties of a new tetramethylfuroquinolinone
RU2282647C1 (ru) Фотосенсибилизаторы для антимикробной фотодинамической терапии
RU2520857C2 (ru) Способ обеззараживания воды и оценки его эффективности
EP1197229A1 (fr) Procédé d'inactivation de micro-organismes
TWI407965B (zh) 一種殺微生物組合
Idil et al. The effect of UV-A and different wavelengths of visible lights on survival of Salmonella typhimurium in seawater microcosms
EP0463202B1 (fr) Composition et méthode pour la stérilisation des pathogènes en présence de l'eau
RU2151601C1 (ru) Способ повышения чувствительности бактерий к биодеструктивному действию лазерного излучения в сочетании с фотосенсибилизатором

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载